Bayer
Bayer aims to boost drugs sales, margins over next 3 years
Olympus sold ‘superbug’ scopes without FDA clearance | Regulatory news for the week of March 9, 2015
Petition accuses Bayer’s Conceptus of altering Essure trial data
Report: Bayer may sell diabetes devices unit to KKR-backed Panasonic Health -report
Report: Bayer explores sale of diabetes device unit
Realizing the value of med-tech innovations
Boston Scientific closes $415 Bayer interventions buy
Boston Scientific (NYSE:BSX) said today that it closed on the $415 million cash buyout of Bayer AG’s interventional unit it announced last May.
Boston Scientific’s peripherals buy bad news for Cardiovascular Systems? | Medtech Wall Street news for the week of May 19, 2014
Is Boston Scientific’s peripherals buy bad news for Cardiovascular Systems?
Boston Scientific’s (NYSE:BSX) $415 million acquisition of Bayer AG’s interventional unit is a strong move for the company, but it may bode ill for other peripheral players.
Boston Scientific bolsters peripheral business with $415M Bayer buy
Boston Scientific (NYSE:BSX) said it agreed to acquire Bayer AG’s interventional unit for $415 million, in a move to significantly bolster its own $200 million peripheral interventions business.